Lindsey E Garrison1, Jessica E Haberer. 1. aCenter for Global Health, Massachusetts General Hospital bHarvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The WHO's Consolidated Guidelines (2016) call for research on improved methods to proactively monitor adherence and identify those individuals who have the greatest needs for adherence support. This review aims to elucidate the latest technologies available to measure adherence to HIV antiretroviral therapy and preexposure prophylaxis against HIV infection and present their utility in various settings and populations. RECENT FINDINGS: Within the last few years, advances have been made in the features of existing technology to measure adherence (real-time electronic adherence measurements), additional approaches have been developed (digital medicine systems) and improved (short message service surveys), and point of care testing for pharmacokinetic measures are under development. SUMMARY: Technology advances in adherence measurement are promising for improved accuracy and, in some cases, the ability to intervene with adherence challenges in real time. This progress will greatly further our understanding of adherence behavior, as well as the ability to effectively link interventions with individuals who need them, thus maximizing the clinical and public health benefits of both antiretroviral therapy and preexposure prophylaxis.
PURPOSE OF REVIEW: The WHO's Consolidated Guidelines (2016) call for research on improved methods to proactively monitor adherence and identify those individuals who have the greatest needs for adherence support. This review aims to elucidate the latest technologies available to measure adherence to HIV antiretroviral therapy and preexposure prophylaxis against HIV infection and present their utility in various settings and populations. RECENT FINDINGS: Within the last few years, advances have been made in the features of existing technology to measure adherence (real-time electronic adherence measurements), additional approaches have been developed (digital medicine systems) and improved (short message service surveys), and point of care testing for pharmacokinetic measures are under development. SUMMARY: Technology advances in adherence measurement are promising for improved accuracy and, in some cases, the ability to intervene with adherence challenges in real time. This progress will greatly further our understanding of adherence behavior, as well as the ability to effectively link interventions with individuals who need them, thus maximizing the clinical and public health benefits of both antiretroviral therapy and preexposure prophylaxis.
Authors: Timothy R Muwonge; Kenneth Ngure; Elly Katabira; Nelly Mugo; Grace Kimemia; Bridget Frances O'Rourke Burns; Nicholas Musinguzi; Felix Bambia; Jared M Baeten; Renee Heffron; Jessica E Haberer Journal: AIDS Behav Date: 2019-05
Authors: Jose R Castillo-Mancilla; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha Mawhinney; Peter L Anderson Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Lauren M Hill; Carol E Golin; Allison Pack; Jessica Carda-Auten; Deshira D Wallace; Sruthi Cherkur; Claire E Farel; Elias P Rosen; Monica Gandhi; Heather M Asher Prince; Angela D M Kashuba Journal: J Assoc Nurses AIDS Care Date: 2020 Jan-Feb Impact factor: 1.354
Authors: Paul K Drain; Ashley R Bardon; Jane M Simoni; Tim R Cressey; Pete Anderson; Derin Sevenler; Ayokunle O Olanrewaju; Monica Gandhi; Connie Celum Journal: Curr HIV/AIDS Rep Date: 2020-10 Impact factor: 5.071
Authors: Kristi Lynn Stringer; Andres Azuero; Corilyn Ott; Christina Psaros; Christina H Jagielski; Steven A Safren; Jessica E Haberer; Mirjam-Colette Kempf Journal: AIDS Behav Date: 2019-05